GLP‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Patients ≥ 80 Years Old With Type 2 Diabetes
GLP-1-Rezeptoragonisten-Therapie und kardiorenale Outcomes bei Patient:innen ≥ 80 Jahre mit Typ-2-Diabetes
Journal of the American Geriatrics Society · 2026-01 · 74 (1) · 96-106
DOI: 10.1111/jgs.70187 ↗Auf einen Blick
Bei 80-Jährigen und Älteren mit Typ-2-Diabetes waren GLP-1-Rezeptoragonisten im Vergleich zu DPP4-Inhibitoren mit geringeren Risiken für kardiovaskuläre, renale und Gesamtmortalitäts-Outcomes verbunden.
Fragestellung
Wie wirksam sind GLP-1-Rezeptoragonisten im Vergleich zu DPP4-Inhibitoren bei Patient:innen ≥ 80 Jahre mit Typ-2-Diabetes?
Methode
Retrospektive Kohortenstudie mit New-User- und aktivem Komparator-Design; Daten aus TriNetX USA von Januar 2018 bis Dezember 2022; Propensity-Score-Matching und Cox-Regression.
Ergebnisse
Nach 1:1-Matching je 11.464 Patient:innen. Geringeres Risiko für MACE (HR 0,86; 95 %-KI 0,81–0,91), MKE (HR 0,86; 95 %-KI 0,82–0,91), Hospitalisierung (HR 0,91; 95 %-KI 0,84–0,97) und Gesamtmortalität (HR 0,82; 95 %-KI 0,77–0,88).
Schlussfolgerung der Autor:innen
GLP-1-Rezeptoragonisten könnten bei Patient:innen ab 80 Jahren mit Typ-2-Diabetes relevante kardiorenale und Überlebensvorteile bieten.
Kernaussagen
- MACE unter GLP-1-RA seltener als unter DPP4i
- Auch MKE, Hospitalisierung und Mortalität niedriger
- Keine Unterschiede bei Herzinsuffizienz oder Frakturen
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Geriatrics Society, online erschienen am 24.10.2025. Verfasst von Jui-Cheng Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Medicine, Shin Kong Wu Huo-Shih Memorial Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Dipeptidyl-Peptidase IV Inhibitors, Hypoglycemic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Shin Kong Wu Ho-Su Memorial Hospital.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated potential in improving glycemic control and reducing adverse outcomes in patients with Type 2 diabetes mellitus (T2DM); however, their efficacy in individuals aged 80 years and older remains understudied. To evaluate the efficacy of GLP‐1 RAs compared with dipeptidyl peptidase‐4 inhibitors (DPP4i) in patients aged ≥ 80 years with T2DM. Participant and Setting De‐identified records from the TriNetX United States database identified 284,417 patients aged ≥ 80 years with T2DM, including 12,032 new GLP‐1 RA users and 28,230 new DPP4i users, analyzed from January 2018 to December 2022.
Methods
This retrospective cohort study utilized a new‐user and active comparator design to evaluate clinical outcomes between GLP‐1 RA and DPP4i users during a follow‐up period of up to 5 years. Propensity score matching, incorporating all the baseline covariates, was used to minimize baseline differences. The Cox proportional hazards regression model was used to estimate hazard ratios (HRs) for clinical outcomes. Sensitivity analyses were performed to validate the findings.
Results
After 1:1 propensity score matching, 11,464 patients were included in each group. Both cohorts had a mean age of 81.6 years; 47.7% were female, and 67% were White. GLP‐1 RA users had significantly lower risks of major adverse cardiovascular events (HR: 0.86, 95% CI: 0.81–0.91), major adverse kidney events (HR: 0.86, 95% CI: 0.82–0.91), all‐cause hospitalization (HR: 0.91, 95% CI: 0.84–0.97), and all‐cause mortality (HR: 0.82, 95% CI: 0.77–0.88) compared with DPP4i users. No significant differences were observed between the groups in the rate of heart failure or bone fractures.
Conclusions
GLP‐1 RAs may offer substantial cardiorenal and survival benefits in patients aged 80 years and older with T2DM. These findings support the use of GLP‐1 RAs as a therapeutic option in this high‐risk, older population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Medicine, Shin Kong Wu Huo-Shih Memorial Hospital, Taipei, Taiwan.
- Division of Nephrology, Department of Internal Medicine, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
- Department of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan.
- Data Analysis Group, Artificial Intelligence Research Center, Research Department, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
- Department of Healthcare Management, National Taipei University of Nursing and Health Sciences, Taipei, Taiwan.
ORCID-Profile: Ming-Hsien Tsai
Förderung
- Shin Kong Wu Ho-Su Memorial Hospital
Zitieren
APA
Chen, J. C., Fang, Y. W., Liu, Y. F., Chen, M. T., & Tsai, M. H. (2026). GLP‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Patients ≥ 80 Years Old With Type 2 Diabetes. Journal of the American Geriatrics Society, 74(1), 96-106. https://doi.org/10.1111/jgs.70187
Vancouver
Chen JC, Fang YW, Liu YF, Chen MT, Tsai MH. GLP‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Patients ≥ 80 Years Old With Type 2 Diabetes. Journal of the American Geriatrics Society. 2026;74(1):96-106. doi:10.1111/jgs.70187
BibTeX
@article{Chen2026,
author = {Chen, Jui-Cheng and Fang, Yu-Wei and Liu, Ya-Fang and Chen, Mon-Ting and Tsai, Ming-Hsien},
title = {GLP‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Patients ≥ 80 Years Old With Type 2 Diabetes},
journal = {Journal of the American Geriatrics Society},
year = {2026},
volume = {74},
number = {1},
pages = {96--106},
doi = {10.1111/jgs.70187}
}
EUVIMED